Patents Issued in May 29, 2018
  • Patent number: 9980993
    Abstract: Compositions and uses thereof include an admixture of a probiotic and natural phytochemicals that can affect an individual's stem cells and the inflammatory process to reduce underlying symptoms of various health issues, including arthritis, aging, and physical or athletic injuries, thereby facilitating healing and repair of tissues.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: May 29, 2018
    Assignee: NWO Stem Cure, LLC
    Inventors: Bruce E. Heck, Dong Hyun Kim
  • Patent number: 9980994
    Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: May 29, 2018
    Assignee: ROBARTS RESEARCH INSTITUTE
    Inventors: John W. Barrett, Grant McFadden
  • Patent number: 9980995
    Abstract: The present invention relates to a method of reducing total gas production and/or methane production in a ruminant animal.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: May 29, 2018
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Meat & Livestock Australia Limited, James Cook University
    Inventors: Lorenna Machado, Marie Elisabeth Magnusson, Nigel William Tomkins, Robert Douglas Kinley, Peter Canisius Denys, Nicholas Andrew Paul
  • Patent number: 9980996
    Abstract: The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: May 29, 2018
    Inventor: Gary J. Speier
  • Patent number: 9980997
    Abstract: A composition and method of improving the overall strength in a mammal, improving fatigue recovery in a mammal, improving athletic recovery in a mammal, improving increased endurance in a mammal, and improving overall athletic performance in a mammal by administering the composition, in the form of a powder, liquid, bar, cookie, waffle, syrup, tablet or dietary supplement, to the mammal. The composition includes 1 to 21.32 grams of cocoa powder; 1 to 48 grams of protein; 0 to 193 grams of carbohydrate; and 0 to 24 grams of fat. The cocoa powder includes 100 to 2,200 mg of cocoa flavanol containing at least one of the derivatives of catechin, (?)-epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, proanthocyanidins, theaflavins, and thearubigins.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: May 29, 2018
    Inventor: James R. Bruno
  • Patent number: 9980998
    Abstract: A medicinal composition having antibiotic, anti-inflammatory, and wound healing activity that inhibits the growth of pathogens by means of a synergistic association of plant extracts of Matricaria recutita, Psidium guajava L., and Plantago major L., and, optionally, Casearia sylvestris SW, for topical application either in the form of biofilm or in the solid dosage form without the use of preservatives is described.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: May 29, 2018
    Assignee: BRAERG—GRUPO BARŚILEIRO DE PESQUISAS ESPECIALIZADAS LTDA.
    Inventors: Douglas Spalato Marques, Marcos Spalato Marques
  • Patent number: 9980999
    Abstract: The invention relates to a method for producing dry extracts of plants and to pharmaceutical preparations containing the same, more particularly phytopharmaceuticals, which contain at least one ethanolic/aqueous extract of a plant (drug), the plants being selected from the group consisting of: Rumicis herba; Verbena officinalis; Sambucus nigra; Primula veris; and Gentiana lutea and mixtures thereof. The invention further relates to a pharmaceutical for treating inflammatory and/or infectious diseases of the nose and throat area and/or the nasal sinuses, as well as the use thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 29, 2018
    Assignee: Binorica SE
    Inventor: Michael Popp
  • Patent number: 9981000
    Abstract: The disclosure provides a medicinal composition for treating diabetes and dyslipidemia obtained from the extract of Costus pictus D. Don. The extract of Costus pictus D. Don includes hydroxycinnamic acid derivatives and flavonol mono-, di- and triglycosides along with small amounts of free flavonols. The extract of Costus pictus D. Don has low levels of oxalic acid and/or oxalates. The hydroxycinnamic acid derivatives include caffeic acid, p-coumaric acid, ferulic acid and sinapic acid and flavonol mono-, di- and triglycosides which include quercetin, kaempferol and isorhamnetin with sugars glucose, galactose and rhamnose. Disclosure also provides a method of preparing the extract of Costus pictus D. Don of the same. The disclosure also provides a method of treating mammals including human beings for medical conditions such as diabetes; dyslipidemia and related conditions; for increasing anti oxidant potential; for the regeneration of pancreatic beta cells and increasing the insulin secretogogue effect.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 29, 2018
    Assignee: ARJUNA NATRUAL EXTRACTS, LTD.
    Inventor: Merina Benny Antony
  • Patent number: 9981001
    Abstract: This invention concerns a method for preventing and treating Colony Collapse Disorder, consisting in the use of an automated device that delivers a diet specifically calibrated for consumption by farm colonies of bees to be treated. The apparatus comprises a box-like container (10) accommodating in its interior at least one reservoir for liquid-tight, accessible from outside through a nozzle (4), an atomizing device of a liquid solution or suspension contained in the reservoir, means for the delivery (2, 1) of the liquid atomized solution or suspension into micrometric drops outside the apparatus, and a control unit programmed for timing the delivery of the solution or suspension to the outside, for the determination of the quantity of solution or suspension delivered and for emitting alarm signals in case of malfunction, the apparatus being powered DC with the energy supplied by a solar panel (5) located outside of the container.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: May 29, 2018
    Assignee: Healthy Bees, LLC.
    Inventor: Francesca Del Vecchio
  • Patent number: 9981002
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 29, 2018
    Assignees: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9981003
    Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 29, 2018
    Assignee: STC.UNM
    Inventor: Jeff Wade Hill
  • Patent number: 9981004
    Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: May 29, 2018
    Assignee: SignaBlok, Inc.
    Inventor: Alexander B. Sigalov
  • Patent number: 9981005
    Abstract: The invention relates to the finding that turnover of DISC1 (Disrupted in schizophrenia 1) is mediated by the F-box-containing protein FBXW7 (F-box/WD repeat-containing protein 7). The sequence within DISC1 that binds to FBXW7 and targets DISC1 for turnover by the ubiquitin-proteasome system is identified. The invention provides antagonists that inhibit this interaction and methods of using these antagonists to decrease DISC1 turnover, for example in treatment of neuropsychiatric disorders, as well as methods of identifying new antagonists.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: May 29, 2018
    Inventor: George Baillie
  • Patent number: 9981006
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 29, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Patent number: 9981007
    Abstract: A drug and/or pharmaceutical composition comprising recombinant mistletoe lectins for treating metastatic tumors, including malignant melanoma such as stage IV malignant melanoma, and use of said drug, particularly in select patient populations, are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain or fragments thereof. Alternatively, the recombinant mistletoe lectin polypeptides can be mistletoe lectin B-chain or fragments thereof. The drug can be used for the treatment of stages III and IV of a metastatic tumor or skin cancer, as well as to treat non-responders and therapeutic failures of a standard tumor therapy. The drug can be used in a dosage in a range of 3-7 ng recombinant mistletoe lectin per kg body weight. The dosage of the recombinant mistletoe lectin can also be 200-500 ng, independently of body weight. The drug can be administered once a week, or more frequently.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: May 29, 2018
    Assignee: Cytavis Biopharma GmbH
    Inventors: Hans Lentzen, Klaus Witthohn
  • Patent number: 9981008
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: May 29, 2018
    Assignee: Cerenis Therapeutics Holding SA
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • Patent number: 9981009
    Abstract: The invention generally relates to the field of biotechnology and medicine. It provides an agent, a pharmaceutical composition and a kit for treatment of autoimmune bullous diseases (AMDB). More specifically, the invention relates to the use of a soluble Fc gamma receptor for treating AMDB, and a pharmaceutical composition and a kit comprising said receptor. It further involves a method of treatment of AMDB.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: May 29, 2018
    Assignee: SUPPREMOL GMBH
    Inventors: Ralf Ludwig, Peter Sondermann, Dominik Ter Meer
  • Patent number: 9981010
    Abstract: A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: May 29, 2018
    Assignees: Baylor College of Medicine, William Marsh Rice University
    Inventors: Alan R. Davis, Elizabeth A. Davis, Kevin Moran, Ronke M. Olabisi, Jennifer L. West, Christy Franco
  • Patent number: 9981011
    Abstract: A method of treating a wound in a diabetic patient is provided. The method includes administering a therapeutically effective amount of Chemokine (C-C motif) ligand 2 (CCL2) to a wound site. In another aspect, a method of treating a wound in a diabetic patient is provided. The method includes assaying a level of CCL2 in the diabetic patient relative to a level of CCL2 in a normal subject and administering a therapeutically effective amount of CCL2 to the diabetic patient.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 29, 2018
    Assignee: Rush University Medical Center
    Inventor: Sasha Shafikhani
  • Patent number: 9981012
    Abstract: The effects of hepcidin treatment on mitigating renal ischemiareperfusion injury (IRI) and acute kidney injury (AKI) by decreasing iron availability and ROS-mediated cell death were tested. C57Bl/6 (WT) and hepcidin knock out (Hamp?/?) mice were treated with saline or 50 ?g of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-heme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-theme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: May 29, 2018
    Assignee: University of Virginia Patent Foundation
    Inventor: Sundararaman Swaminathan
  • Patent number: 9981013
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Patent number: 9981014
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 29, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Patent number: 9981015
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 29, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Patent number: 9981016
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 29, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Patent number: 9981017
    Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: May 29, 2018
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
  • Patent number: 9981018
    Abstract: A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: May 29, 2018
    Assignee: The Cleveland Clinic Foundation
    Inventor: Tatiana Byzova
  • Patent number: 9981019
    Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 29, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
  • Patent number: 9981020
    Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 29, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Kamel Khalili, Wenhui Hu
  • Patent number: 9981021
    Abstract: Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 29, 2018
    Assignee: KINETIQ, INC.
    Inventors: Mingju Cao, Alexander M. Cao
  • Patent number: 9981022
    Abstract: A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: May 29, 2018
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 9981023
    Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition thatco-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: May 29, 2018
    Assignee: The Scripps Research Institute
    Inventors: James C. Paulson, Matthew MacAuley, David Nemazee
  • Patent number: 9981024
    Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 29, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew Seavey, Yvonne Paterson, Paulo Maciag, Duane Sewell
  • Patent number: 9981025
    Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 29, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Shi-Xian Deng, Donald W. Landry, Gavreel Kalantarov, Ilya Trakht
  • Patent number: 9981026
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: May 29, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Patent number: 9981027
    Abstract: The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 29, 2018
    Assignees: IDEMITSU KOSAN CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
    Inventors: Kazutoshi Sawada, Takeshi Matsui, Eiji Takita, Takashi Hamabata, Toshio Sato
  • Patent number: 9981028
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: May 29, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Lisa L. Herron-Olson, Laura Wonderling
  • Patent number: 9981029
    Abstract: Provided is an immunogenic composition comprising 13 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from a different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, 12 serotypes selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F and serotype 2 or 9N. The immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases coverage with respect to pneumococcal diseases in infants and children.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: May 29, 2018
    Assignee: SK Chemical Co., Ltd.
    Inventors: Mahn-Hoon Park, Hun Kim, Ji-Hye Yang, Seon-Young Yang, Myeong-Ju Noh, Su-Jin Park, Jin-Hwan Shin
  • Patent number: 9981030
    Abstract: Described herein are synthetic glycan conjugates comprising a carrier and a glycan moiety derived from Neisseria meningitidis, wherein the glycan moiety is covalently linked to the carrier through a linker. Also provided herein are a mixture of the glycan conjugates thereof, immmunogenic compositions thereof, and kits thereof. The invention further provides methods of using the synthetic glycan conjugates and immunogenic compositions thereof to treat and/or reduce the risk of infectious diseases such as bacterial infections.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 29, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Chia-Hung Wang, Shiou-Ting Li
  • Patent number: 9981031
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 29, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Costantino
  • Patent number: 9981032
    Abstract: Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of Escherichia coli (E. coli), Trueperella pyogenes (T. pyogenes), Fusobacterium necrophorum (F. necrophorum) and combinations thereof; and/or proteins selected from F. necrophorum leukotoxin (LKT), E. coli type 1 fimbrial adhesin (FimH), T. pyogenes pyolysin (PLO), and all combinations of the whole cells and the proteins.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 29, 2018
    Assignee: Cornell University
    Inventors: Rodrigo Carvalho Bicalho, Robert Owen Gilbert, Vinicius Machado, Marcela Bicalho
  • Patent number: 9981033
    Abstract: The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 29, 2018
    Assignee: MERIAL INC.
    Inventors: Teshome Mebatsion, Aemro Kassa, Taejoong Kim
  • Patent number: 9981034
    Abstract: Disclosed herein are compositions and methods useful for immunizing a subject against disease caused by influenza A. Disclosed methods comprise administering to the subject an immunoprotective dose of an immunogenic composition. In certain aspects, the immunogenic composition is a vaccine comprised of a recombinant chimeric hemagglutinin polypeptide. In certain aspects, the subject is a mammal. In further aspects, the mammal is a pig. In still further aspects, the mammal is a human.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 29, 2018
    Assignee: South Dakota Board of Regents
    Inventors: Victor Huber, Ying Fang
  • Patent number: 9981035
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 29, 2018
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Patent number: 9981036
    Abstract: Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL 12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: May 29, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Matthew P. Morrow, Jian Yan
  • Patent number: 9981037
    Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, ?-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with ?-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 29, 2018
    Assignees: The Brigham and Women's Hospital, Inc., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron Ilan, Howard L. Weiner
  • Patent number: 9981038
    Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of HDAC having photoswitchable modulators of protein function with short thermal relaxation kinetics. The compounds are diazo compounds including a substituted or unsubstituted aryl or heteroaryl ring, wherein at least one of the rings is substituted with one or more HDAC targeting elements.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 29, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
  • Patent number: 9981039
    Abstract: This invention pertains to a zafirlukast-containing composition, a method of preparing the composition, and a method for treating certain skin disorders using the zafirlukast-containing composition.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 29, 2018
    Inventor: Amey Mahajan
  • Patent number: 9981040
    Abstract: An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: May 29, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Yosuke Ueki
  • Patent number: 9981041
    Abstract: An ophthalmic composition for administration as a spray to the eye is provided. The ophthalmic composition comprises a lubricant comprising hydroxypropyl methylcellulose (HPMC), mineral oil, and sterile water. The ophthalmic composition is also configured as a delivery vehicle for administration of ophthalmic pharmaceuticals to the eye. A method of treating keratoconjunctivitis sicca by administering the ophthalmic composition is also provided.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: May 29, 2018
    Inventor: Ira Jason Salzman
  • Patent number: 9981042
    Abstract: The present invention provides an anticancer agent comprising a multi-walled carbon nanotube and an anticancer drug covalently attached to the surface of the multi-walled carbon nanotube, in order to anticancer agent capable of solving drug resistance problem.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 29, 2018
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Dong Woo Khang, Sang Soo Kang, Jungil Choi, Tae Hyun Nam